Trisalus Life Sciences Said It Received Approval From The World Health Organization And The American Medical Association's Adopted Name Council For "nelitolimod" As The Nonproprietary Drug Name For SD-101
Portfolio Pulse from Benzinga Newsdesk
Trisalus Life Sciences has received approval from the World Health Organization and the American Medical Association's Adopted Name Council for 'nelitolimod' as the nonproprietary name for its drug SD-101.
March 07, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trisalus Life Sciences' drug SD-101 has been officially named 'nelitolimod' by WHO and AMA, marking a significant regulatory milestone.
The approval of a nonproprietary name for a drug is a crucial step in the regulatory process, indicating progress towards commercialization. This news is likely to be viewed positively by investors and could lead to increased investor confidence in Trisalus Life Sciences, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90